http://www.mypharma-editions.com L'Info Industrie & Politique de Santé Wed, 15 Feb 2012 14:04:44 +0000 en hourly 1 http://wordpress.org/?v=3.3.1 http://www.mypharma-editions.com/biogen-idec-va-acquerir-stromedix http://www.mypharma-editions.com/biogen-idec-va-acquerir-stromedix#comments Tue, 14 Feb 2012 17:08:58 +0000 morgdave http://www.mypharma-editions.com/?p=23426 http://www.mypharma-editions.com/biogen-idec-va-acquerir-stromedix/feed 0 http://www.mypharma-editions.com/vih-innavirvax-annonce-une-levee-de-fonds-de-37-millions-deuros http://www.mypharma-editions.com/vih-innavirvax-annonce-une-levee-de-fonds-de-37-millions-deuros#comments Mon, 13 Feb 2012 15:06:12 +0000 morgdave http://www.mypharma-editions.com/?p=23410 http://www.mypharma-editions.com/vih-innavirvax-annonce-une-levee-de-fonds-de-37-millions-deuros/feed 0 http://www.mypharma-editions.com/maladies-auto-immunes-effimune-recoit-un-soutien-financier-de-lue-pour-le-projet-triad http://www.mypharma-editions.com/maladies-auto-immunes-effimune-recoit-un-soutien-financier-de-lue-pour-le-projet-triad#comments Mon, 13 Feb 2012 09:50:44 +0000 morgdave http://www.mypharma-editions.com/?p=23407 http://www.mypharma-editions.com/maladies-auto-immunes-effimune-recoit-un-soutien-financier-de-lue-pour-le-projet-triad/feed 0 http://www.mypharma-editions.com/pharnext-leve-8-millions-deuros-supplementaires-pour-sa-plateforme-de-pleotherapie http://www.mypharma-editions.com/pharnext-leve-8-millions-deuros-supplementaires-pour-sa-plateforme-de-pleotherapie#comments Thu, 09 Feb 2012 09:47:36 +0000 morgdave http://www.mypharma-editions.com/?p=23378 http://www.mypharma-editions.com/pharnext-leve-8-millions-deuros-supplementaires-pour-sa-plateforme-de-pleotherapie/feed 0 http://www.mypharma-editions.com/immunotherapie-en-france-un-constat-mitige-selon-une-etude-du-leem http://www.mypharma-editions.com/immunotherapie-en-france-un-constat-mitige-selon-une-etude-du-leem#comments Wed, 08 Feb 2012 17:53:18 +0000 morgdave http://www.mypharma-editions.com/?p=23369 http://www.mypharma-editions.com/immunotherapie-en-france-un-constat-mitige-selon-une-etude-du-leem/feed 0 http://www.mypharma-editions.com/le-genopole-pilote-la-formation-dacteurs-dun-biocluster-polonais http://www.mypharma-editions.com/le-genopole-pilote-la-formation-dacteurs-dun-biocluster-polonais#comments Tue, 07 Feb 2012 14:32:34 +0000 morgdave http://www.mypharma-editions.com/?p=23355 http://www.mypharma-editions.com/le-genopole-pilote-la-formation-dacteurs-dun-biocluster-polonais/feed 0 http://www.mypharma-editions.com/alize-pharma-cede-une-licence-a-eusa-pharma-sur-son-programme-asparec http://www.mypharma-editions.com/alize-pharma-cede-une-licence-a-eusa-pharma-sur-son-programme-asparec#comments Mon, 06 Feb 2012 15:01:36 +0000 morgdave http://www.mypharma-editions.com/?p=23341 http://www.mypharma-editions.com/alize-pharma-cede-une-licence-a-eusa-pharma-sur-son-programme-asparec/feed 0 http://www.mypharma-editions.com/diabete-adocia-recoit-10-m-au-titre-de-son-accord-de-licence-avec-eli-lilly http://www.mypharma-editions.com/diabete-adocia-recoit-10-m-au-titre-de-son-accord-de-licence-avec-eli-lilly#comments Mon, 06 Feb 2012 09:40:38 +0000 morgdave http://www.mypharma-editions.com/?p=23335 http://www.mypharma-editions.com/diabete-adocia-recoit-10-m-au-titre-de-son-accord-de-licence-avec-eli-lilly/feed 0 http://www.mypharma-editions.com/maladies-metaboliques-kinemed-annonce-sa-collaboration-avec-pfizer http://www.mypharma-editions.com/maladies-metaboliques-kinemed-annonce-sa-collaboration-avec-pfizer#comments Wed, 01 Feb 2012 08:56:03 +0000 morgdave http://www.mypharma-editions.com/?p=23288 http://www.mypharma-editions.com/maladies-metaboliques-kinemed-annonce-sa-collaboration-avec-pfizer/feed 0 http://www.mypharma-editions.com/transgene-franchit-deux-nouvelles-etapes-pour-ses-activites-en-chine http://www.mypharma-editions.com/transgene-franchit-deux-nouvelles-etapes-pour-ses-activites-en-chine#comments Tue, 31 Jan 2012 09:29:31 +0000 morgdave http://www.mypharma-editions.com/?p=23282 http://www.mypharma-editions.com/transgene-franchit-deux-nouvelles-etapes-pour-ses-activites-en-chine/feed 0 http://www.mypharma-editions.com/maladie-de-parkinson-domain-therapeutics-obtient-une-subvention-de-la-fondation-michael-j-fox http://www.mypharma-editions.com/maladie-de-parkinson-domain-therapeutics-obtient-une-subvention-de-la-fondation-michael-j-fox#comments Tue, 31 Jan 2012 09:17:51 +0000 morgdave http://www.mypharma-editions.com/?p=23278 http://www.mypharma-editions.com/maladie-de-parkinson-domain-therapeutics-obtient-une-subvention-de-la-fondation-michael-j-fox/feed 0 http://www.mypharma-editions.com/biogen-idec-kenneth-dipietro-nomme-vice-president-executif-des-ressources-humaines http://www.mypharma-editions.com/biogen-idec-kenneth-dipietro-nomme-vice-president-executif-des-ressources-humaines#comments Mon, 30 Jan 2012 14:50:54 +0000 morgdave http://www.mypharma-editions.com/?p=23251 http://www.mypharma-editions.com/biogen-idec-kenneth-dipietro-nomme-vice-president-executif-des-ressources-humaines/feed 0 http://www.mypharma-editions.com/biotechs-amgen-rachete-micromet-pour-116-milliard-de-dollars http://www.mypharma-editions.com/biotechs-amgen-rachete-micromet-pour-116-milliard-de-dollars#comments Mon, 30 Jan 2012 09:34:17 +0000 morgdave http://www.mypharma-editions.com/?p=23237 http://www.mypharma-editions.com/biotechs-amgen-rachete-micromet-pour-116-milliard-de-dollars/feed 0 http://www.mypharma-editions.com/biotechs-rhenovia-pharma-ouvre-sa-premiere-filiale-internationale-aux-etats-unis http://www.mypharma-editions.com/biotechs-rhenovia-pharma-ouvre-sa-premiere-filiale-internationale-aux-etats-unis#comments Fri, 27 Jan 2012 14:17:31 +0000 morgdave http://www.mypharma-editions.com/?p=23227 http://www.mypharma-editions.com/biotechs-rhenovia-pharma-ouvre-sa-premiere-filiale-internationale-aux-etats-unis/feed 0 http://www.mypharma-editions.com/bioalliance-pharma-confirme-la-dynamique-de-ses-fondamentaux-pour-2012 http://www.mypharma-editions.com/bioalliance-pharma-confirme-la-dynamique-de-ses-fondamentaux-pour-2012#comments Fri, 27 Jan 2012 14:02:27 +0000 morgdave http://www.mypharma-editions.com/?p=23224 http://www.mypharma-editions.com/bioalliance-pharma-confirme-la-dynamique-de-ses-fondamentaux-pour-2012/feed 0 http://www.mypharma-editions.com/vivalis-inaugure-un-laboratoire-dedie-a-sa-plateforme-de-decouverte-danticorps-monoclonaux-vivascreen http://www.mypharma-editions.com/vivalis-inaugure-un-laboratoire-dedie-a-sa-plateforme-de-decouverte-danticorps-monoclonaux-vivascreen#comments Wed, 25 Jan 2012 09:18:53 +0000 morgdave http://www.mypharma-editions.com/?p=23185 http://www.mypharma-editions.com/vivalis-inaugure-un-laboratoire-dedie-a-sa-plateforme-de-decouverte-danticorps-monoclonaux-vivascreen/feed 0 http://www.mypharma-editions.com/genzyme-la-fda-approuve-a-son-tour-le-site-de-production-de-framingham http://www.mypharma-editions.com/genzyme-la-fda-approuve-a-son-tour-le-site-de-production-de-framingham#comments Tue, 24 Jan 2012 08:04:45 +0000 morgdave http://www.mypharma-editions.com/?p=23163 http://www.mypharma-editions.com/genzyme-la-fda-approuve-a-son-tour-le-site-de-production-de-framingham/feed 0 http://www.mypharma-editions.com/bioalliance-pharma-deux-nouvelles-etapes-cles-pour-sa-biotherapie-amep-dans-le-melanome-metastatique http://www.mypharma-editions.com/bioalliance-pharma-deux-nouvelles-etapes-cles-pour-sa-biotherapie-amep-dans-le-melanome-metastatique#comments Mon, 23 Jan 2012 17:22:09 +0000 morgdave http://www.mypharma-editions.com/?p=23158 http://www.mypharma-editions.com/bioalliance-pharma-deux-nouvelles-etapes-cles-pour-sa-biotherapie-amep-dans-le-melanome-metastatique/feed 0 http://www.mypharma-editions.com/la-fda-met-a-jour-letiquetage-de-tysabri-natalizumab http://www.mypharma-editions.com/la-fda-met-a-jour-letiquetage-de-tysabri-natalizumab#comments Mon, 23 Jan 2012 07:52:00 +0000 morgdave http://www.mypharma-editions.com/?p=23119 http://www.mypharma-editions.com/la-fda-met-a-jour-letiquetage-de-tysabri-natalizumab/feed 0 http://www.mypharma-editions.com/cancer-quintiles-investit-dans-une-nouvelle-societe-de-rd-de-biomarqueurs http://www.mypharma-editions.com/cancer-quintiles-investit-dans-une-nouvelle-societe-de-rd-de-biomarqueurs#comments Thu, 19 Jan 2012 13:29:01 +0000 morgdave http://www.mypharma-editions.com/?p=23084 http://www.mypharma-editions.com/cancer-quintiles-investit-dans-une-nouvelle-societe-de-rd-de-biomarqueurs/feed 0 http://www.mypharma-editions.com/hybrigenics-depose-une-demande-detude-clinique-pour-linecalcitol-dans-la-leucemie-lymphoide-chronique-llc http://www.mypharma-editions.com/hybrigenics-depose-une-demande-detude-clinique-pour-linecalcitol-dans-la-leucemie-lymphoide-chronique-llc#comments Thu, 19 Jan 2012 13:22:46 +0000 morgdave http://www.mypharma-editions.com/?p=23082 http://www.mypharma-editions.com/hybrigenics-depose-une-demande-detude-clinique-pour-linecalcitol-dans-la-leucemie-lymphoide-chronique-llc/feed 0 http://www.mypharma-editions.com/pherecydes-pharma-obtient-un-financement-de-la-dga-pour-le-projet-pacoburns http://www.mypharma-editions.com/pherecydes-pharma-obtient-un-financement-de-la-dga-pour-le-projet-pacoburns#comments Thu, 19 Jan 2012 09:11:07 +0000 morgdave http://www.mypharma-editions.com/?p=23078 http://www.mypharma-editions.com/pherecydes-pharma-obtient-un-financement-de-la-dga-pour-le-projet-pacoburns/feed 0 http://www.mypharma-editions.com/astellas-feu-vert-au-japon-pour-regnite-contre-le-syndrome-des-jambes-sans-repos http://www.mypharma-editions.com/astellas-feu-vert-au-japon-pour-regnite-contre-le-syndrome-des-jambes-sans-repos#comments Thu, 19 Jan 2012 09:00:04 +0000 morgdave http://www.mypharma-editions.com/?p=23074 http://www.mypharma-editions.com/astellas-feu-vert-au-japon-pour-regnite-contre-le-syndrome-des-jambes-sans-repos/feed 0 http://www.mypharma-editions.com/quintiles-ouvre-un-centre-dexcellence-novateur-a-dalian-en-chine http://www.mypharma-editions.com/quintiles-ouvre-un-centre-dexcellence-novateur-a-dalian-en-chine#comments Wed, 18 Jan 2012 16:23:18 +0000 morgdave http://www.mypharma-editions.com/?p=23063 http://www.mypharma-editions.com/quintiles-ouvre-un-centre-dexcellence-novateur-a-dalian-en-chine/feed 0 http://www.mypharma-editions.com/maladies-infectieuses-vivalis-et-sanofi-pasteur-etendent-leur-accord-de-collboration http://www.mypharma-editions.com/maladies-infectieuses-vivalis-et-sanofi-pasteur-etendent-leur-accord-de-collboration#comments Wed, 18 Jan 2012 08:25:21 +0000 morgdave http://www.mypharma-editions.com/?p=23046 http://www.mypharma-editions.com/maladies-infectieuses-vivalis-et-sanofi-pasteur-etendent-leur-accord-de-collboration/feed 0 http://www.mypharma-editions.com/genzyme-son-site-de-production-de-framingham-approuve-par-les-autorites-europeennes http://www.mypharma-editions.com/genzyme-son-site-de-production-de-framingham-approuve-par-les-autorites-europeennes#comments Wed, 18 Jan 2012 08:16:58 +0000 morgdave http://www.mypharma-editions.com/?p=23043 http://www.mypharma-editions.com/genzyme-son-site-de-production-de-framingham-approuve-par-les-autorites-europeennes/feed 0 http://www.mypharma-editions.com/michele-antonelli-nomme-vice-president-executif-et-directeur-general-ducb-france http://www.mypharma-editions.com/michele-antonelli-nomme-vice-president-executif-et-directeur-general-ducb-france#comments Mon, 16 Jan 2012 15:13:06 +0000 morgdave http://www.mypharma-editions.com/?p=23021 http://www.mypharma-editions.com/michele-antonelli-nomme-vice-president-executif-et-directeur-general-ducb-france/feed 0 http://www.mypharma-editions.com/medicago-et-cellectis-collaborent-a-lamelioration-des-proteines-therapeutiques-grace-a-la-technologie-des-nucleases http://www.mypharma-editions.com/medicago-et-cellectis-collaborent-a-lamelioration-des-proteines-therapeutiques-grace-a-la-technologie-des-nucleases#comments Mon, 16 Jan 2012 08:01:52 +0000 morgdave http://www.mypharma-editions.com/?p=23009 http://www.mypharma-editions.com/medicago-et-cellectis-collaborent-a-lamelioration-des-proteines-therapeutiques-grace-a-la-technologie-des-nucleases/feed 0 http://www.mypharma-editions.com/stallergenes-vise-une-croissance-de-5-a-7-en-2012 http://www.mypharma-editions.com/stallergenes-vise-une-croissance-de-5-a-7-en-2012#comments Fri, 13 Jan 2012 08:41:19 +0000 morgdave http://www.mypharma-editions.com/?p=22999 http://www.mypharma-editions.com/stallergenes-vise-une-croissance-de-5-a-7-en-2012/feed 2 http://www.mypharma-editions.com/biotechnologies-inserm-transfert-initiative-leve-335-millions-deuros http://www.mypharma-editions.com/biotechnologies-inserm-transfert-initiative-leve-335-millions-deuros#comments Thu, 12 Jan 2012 13:38:29 +0000 morgdave http://www.mypharma-editions.com/?p=22990 http://www.mypharma-editions.com/biotechnologies-inserm-transfert-initiative-leve-335-millions-deuros/feed 0 http://www.mypharma-editions.com/biotechs-sanofi-investit-dans-warp-drive-bio-une-start-up-americaine http://www.mypharma-editions.com/biotechs-sanofi-investit-dans-warp-drive-bio-une-start-up-americaine#comments Tue, 10 Jan 2012 13:23:17 +0000 morgdave http://www.mypharma-editions.com/?p=22951 http://www.mypharma-editions.com/biotechs-sanofi-investit-dans-warp-drive-bio-une-start-up-americaine/feed 2 http://www.mypharma-editions.com/epilepsie-premiers-resultats-positifs-dans-letude-phase-ii-sur-vimpat-ducb http://www.mypharma-editions.com/epilepsie-premiers-resultats-positifs-dans-letude-phase-ii-sur-vimpat-ducb#comments Mon, 09 Jan 2012 08:42:04 +0000 morgdave http://www.mypharma-editions.com/?p=22943 http://www.mypharma-editions.com/epilepsie-premiers-resultats-positifs-dans-letude-phase-ii-sur-vimpat-ducb/feed 0 http://www.mypharma-editions.com/hepatite-c-bristol-myers-squibb-acquiert-inhibitex-pour-25-milliards-de-dollars http://www.mypharma-editions.com/hepatite-c-bristol-myers-squibb-acquiert-inhibitex-pour-25-milliards-de-dollars#comments Sun, 08 Jan 2012 15:08:32 +0000 morgdave http://www.mypharma-editions.com/?p=22941 http://www.mypharma-editions.com/hepatite-c-bristol-myers-squibb-acquiert-inhibitex-pour-25-milliards-de-dollars/feed 1 http://www.mypharma-editions.com/neovacs-letude-clinique-de-phase-iia-dans-la-polyarthrite-rhumatoide-atteint-ses-objectifs http://www.mypharma-editions.com/neovacs-letude-clinique-de-phase-iia-dans-la-polyarthrite-rhumatoide-atteint-ses-objectifs#comments Thu, 05 Jan 2012 08:27:09 +0000 morgdave http://www.mypharma-editions.com/?p=22929 http://www.mypharma-editions.com/neovacs-letude-clinique-de-phase-iia-dans-la-polyarthrite-rhumatoide-atteint-ses-objectifs/feed 1 http://www.mypharma-editions.com/biogen-idec-et-isis-pharmaceuticals-vont-developper-un-programme-antisens-ciblant-latrophie-musculaire-spinale http://www.mypharma-editions.com/biogen-idec-et-isis-pharmaceuticals-vont-developper-un-programme-antisens-ciblant-latrophie-musculaire-spinale#comments Wed, 04 Jan 2012 15:27:22 +0000 morgdave http://www.mypharma-editions.com/?p=22920 http://www.mypharma-editions.com/biogen-idec-et-isis-pharmaceuticals-vont-developper-un-programme-antisens-ciblant-latrophie-musculaire-spinale/feed 0 http://www.mypharma-editions.com/accord-entre-arecor-et-lilly-pour-developper-des-formulations-avancees-de-medicaments-proteiques http://www.mypharma-editions.com/accord-entre-arecor-et-lilly-pour-developper-des-formulations-avancees-de-medicaments-proteiques#comments Thu, 22 Dec 2011 09:16:37 +0000 morgdave http://www.mypharma-editions.com/?p=22864 http://www.mypharma-editions.com/accord-entre-arecor-et-lilly-pour-developper-des-formulations-avancees-de-medicaments-proteiques/feed 0 http://www.mypharma-editions.com/maladie-de-parkinson-proteotech-et-glaxosmithkline-collaborent-au-developpement-dune-nouvelle-therapie http://www.mypharma-editions.com/maladie-de-parkinson-proteotech-et-glaxosmithkline-collaborent-au-developpement-dune-nouvelle-therapie#comments Tue, 20 Dec 2011 16:42:07 +0000 morgdave http://www.mypharma-editions.com/?p=22837 http://www.mypharma-editions.com/maladie-de-parkinson-proteotech-et-glaxosmithkline-collaborent-au-developpement-dune-nouvelle-therapie/feed 1 http://www.mypharma-editions.com/genoway-signe-des-partenariats-avec-deux-prestigieuses-universites-americaines http://www.mypharma-editions.com/genoway-signe-des-partenariats-avec-deux-prestigieuses-universites-americaines#comments Tue, 20 Dec 2011 09:14:30 +0000 morgdave http://www.mypharma-editions.com/?p=22829 http://www.mypharma-editions.com/genoway-signe-des-partenariats-avec-deux-prestigieuses-universites-americaines/feed 0 http://www.mypharma-editions.com/genzyme-premiers-resultats-de-letude-tenere-sur-le-teriflunomide-dans-la-sclerose-en-plaques http://www.mypharma-editions.com/genzyme-premiers-resultats-de-letude-tenere-sur-le-teriflunomide-dans-la-sclerose-en-plaques#comments Tue, 20 Dec 2011 08:36:55 +0000 morgdave http://www.mypharma-editions.com/?p=22824 http://www.mypharma-editions.com/genzyme-premiers-resultats-de-letude-tenere-sur-le-teriflunomide-dans-la-sclerose-en-plaques/feed 0 http://www.mypharma-editions.com/psoriasis-hybrigenics-acheve-le-recrutement-de-letude-clinique-de-phase-ii-de-linecalcitol http://www.mypharma-editions.com/psoriasis-hybrigenics-acheve-le-recrutement-de-letude-clinique-de-phase-ii-de-linecalcitol#comments Mon, 19 Dec 2011 13:53:05 +0000 morgdave http://www.mypharma-editions.com/?p=22815 http://www.mypharma-editions.com/psoriasis-hybrigenics-acheve-le-recrutement-de-letude-clinique-de-phase-ii-de-linecalcitol/feed 0 http://www.mypharma-editions.com/biotherapies-transgene-et-la-ligue-nationale-contre-le-cancer-signent-un-partenariat http://www.mypharma-editions.com/biotherapies-transgene-et-la-ligue-nationale-contre-le-cancer-signent-un-partenariat#comments Fri, 16 Dec 2011 09:33:46 +0000 morgdave http://www.mypharma-editions.com/?p=22795 http://www.mypharma-editions.com/biotherapies-transgene-et-la-ligue-nationale-contre-le-cancer-signent-un-partenariat/feed 0 http://www.mypharma-editions.com/maladie-de-crohn-neovacs-finalise-le-recrutement-de-patients-dans-letude-de-phase-ii-avec-le-tnf-kinoide http://www.mypharma-editions.com/maladie-de-crohn-neovacs-finalise-le-recrutement-de-patients-dans-letude-de-phase-ii-avec-le-tnf-kinoide#comments Thu, 15 Dec 2011 08:25:58 +0000 morgdave http://www.mypharma-editions.com/?p=22772 http://www.mypharma-editions.com/maladie-de-crohn-neovacs-finalise-le-recrutement-de-patients-dans-letude-de-phase-ii-avec-le-tnf-kinoide/feed 0 http://www.mypharma-editions.com/alliance-entre-ge-healthcare-et-mw-group-dans-les-produits-biopharmaceutiques-vitaux http://www.mypharma-editions.com/alliance-entre-ge-healthcare-et-mw-group-dans-les-produits-biopharmaceutiques-vitaux#comments Thu, 15 Dec 2011 08:12:19 +0000 morgdave http://www.mypharma-editions.com/?p=22766 http://www.mypharma-editions.com/alliance-entre-ge-healthcare-et-mw-group-dans-les-produits-biopharmaceutiques-vitaux/feed 1 http://www.mypharma-editions.com/feu-vert-de-lue-pour-dificlir-dastellas-pharma http://www.mypharma-editions.com/feu-vert-de-lue-pour-dificlir-dastellas-pharma#comments Wed, 14 Dec 2011 10:49:31 +0000 morgdave http://www.mypharma-editions.com/?p=22755 http://www.mypharma-editions.com/feu-vert-de-lue-pour-dificlir-dastellas-pharma/feed 0 http://www.mypharma-editions.com/alzheimer-exonhit-lance-une-etude-observationnelle-sur-son-test-aclarusdx%c2%ae-en-france http://www.mypharma-editions.com/alzheimer-exonhit-lance-une-etude-observationnelle-sur-son-test-aclarusdx%c2%ae-en-france#comments Tue, 13 Dec 2011 07:42:47 +0000 morgdave http://www.mypharma-editions.com/?p=22703 http://www.mypharma-editions.com/alzheimer-exonhit-lance-une-etude-observationnelle-sur-son-test-aclarusdx%c2%ae-en-france/feed 0 http://www.mypharma-editions.com/vih-gilead-annonce-les-donnees-sur-deux-ans-dune-etude-pivot-de-phase-3-sur-lelvitegravir http://www.mypharma-editions.com/vih-gilead-annonce-les-donnees-sur-deux-ans-dune-etude-pivot-de-phase-3-sur-lelvitegravir#comments Mon, 12 Dec 2011 08:41:53 +0000 morgdave http://www.mypharma-editions.com/?p=22677 http://www.mypharma-editions.com/vih-gilead-annonce-les-donnees-sur-deux-ans-dune-etude-pivot-de-phase-3-sur-lelvitegravir/feed 1 http://www.mypharma-editions.com/cellectis-bioresearch-et-syngene-partenaires-pour-le-developpement-de-lignees-cellulaires-personnalisees http://www.mypharma-editions.com/cellectis-bioresearch-et-syngene-partenaires-pour-le-developpement-de-lignees-cellulaires-personnalisees#comments Fri, 09 Dec 2011 08:51:30 +0000 morgdave http://www.mypharma-editions.com/?p=22647 http://www.mypharma-editions.com/cellectis-bioresearch-et-syngene-partenaires-pour-le-developpement-de-lignees-cellulaires-personnalisees/feed 0 http://www.mypharma-editions.com/integragen-laurence-riot-lamotte-nommee-directeur-administratif-et-financier http://www.mypharma-editions.com/integragen-laurence-riot-lamotte-nommee-directeur-administratif-et-financier#comments Fri, 09 Dec 2011 07:47:53 +0000 morgdave http://www.mypharma-editions.com/?p=22638 http://www.mypharma-editions.com/integragen-laurence-riot-lamotte-nommee-directeur-administratif-et-financier/feed 0 http://www.mypharma-editions.com/cellectis-signe-un-accord-de-licence-avec-novartis http://www.mypharma-editions.com/cellectis-signe-un-accord-de-licence-avec-novartis#comments Tue, 06 Dec 2011 13:02:58 +0000 morgdave http://www.mypharma-editions.com/?p=22601 http://www.mypharma-editions.com/cellectis-signe-un-accord-de-licence-avec-novartis/feed 0 http://www.mypharma-editions.com/biosimilaires-samsung-et-biogen-idec-creent-une-coentreprise http://www.mypharma-editions.com/biosimilaires-samsung-et-biogen-idec-creent-une-coentreprise#comments Tue, 06 Dec 2011 08:48:09 +0000 morgdave http://www.mypharma-editions.com/?p=22584 http://www.mypharma-editions.com/biosimilaires-samsung-et-biogen-idec-creent-une-coentreprise/feed 1 http://www.mypharma-editions.com/vih-le-cobicistat-de-gilead-atteint-son-objectif-principal-lors-dune-etude-decisive-de-phase-3 http://www.mypharma-editions.com/vih-le-cobicistat-de-gilead-atteint-son-objectif-principal-lors-dune-etude-decisive-de-phase-3#comments Tue, 06 Dec 2011 08:20:44 +0000 morgdave http://www.mypharma-editions.com/?p=22581 http://www.mypharma-editions.com/vih-le-cobicistat-de-gilead-atteint-son-objectif-principal-lors-dune-etude-decisive-de-phase-3/feed 0 http://www.mypharma-editions.com/le-parc-technologique-biocitech-annonce-l%e2%80%99arrivee-sur-son-site-de-biobank-for-life http://www.mypharma-editions.com/le-parc-technologique-biocitech-annonce-l%e2%80%99arrivee-sur-son-site-de-biobank-for-life#comments Fri, 02 Dec 2011 08:36:29 +0000 morgdave http://www.mypharma-editions.com/?p=22551 http://www.mypharma-editions.com/le-parc-technologique-biocitech-annonce-l%e2%80%99arrivee-sur-son-site-de-biobank-for-life/feed 0 http://www.mypharma-editions.com/nicox-va-reduire-d%e2%80%99un-tiers-ses-effectifs http://www.mypharma-editions.com/nicox-va-reduire-d%e2%80%99un-tiers-ses-effectifs#comments Thu, 01 Dec 2011 08:26:13 +0000 morgdave http://www.mypharma-editions.com/?p=22516 http://www.mypharma-editions.com/nicox-va-reduire-d%e2%80%99un-tiers-ses-effectifs/feed 0 http://www.mypharma-editions.com/hemophilie-le-partenaire-d%e2%80%99ipsen-inspiration-initie-la-seconde-etude-pivotale-de-phase-iii-avec-obi-1 http://www.mypharma-editions.com/hemophilie-le-partenaire-d%e2%80%99ipsen-inspiration-initie-la-seconde-etude-pivotale-de-phase-iii-avec-obi-1#comments Mon, 28 Nov 2011 07:33:05 +0000 morgdave http://www.mypharma-editions.com/?p=22488 http://www.mypharma-editions.com/hemophilie-le-partenaire-d%e2%80%99ipsen-inspiration-initie-la-seconde-etude-pivotale-de-phase-iii-avec-obi-1/feed 0 http://www.mypharma-editions.com/genfit-nouvelles-donnees-precliniques-positives-pour-le-gft505 http://www.mypharma-editions.com/genfit-nouvelles-donnees-precliniques-positives-pour-le-gft505#comments Sat, 26 Nov 2011 08:59:59 +0000 morgdave http://www.mypharma-editions.com/?p=22480 http://www.mypharma-editions.com/genfit-nouvelles-donnees-precliniques-positives-pour-le-gft505/feed 0 http://www.mypharma-editions.com/pharmaleads-annonce-lentree-en-phase-2-du-pl37-chef-de-file-dune-nouvelle-classe-danalgesiques http://www.mypharma-editions.com/pharmaleads-annonce-lentree-en-phase-2-du-pl37-chef-de-file-dune-nouvelle-classe-danalgesiques#comments Fri, 25 Nov 2011 14:17:42 +0000 morgdave http://www.mypharma-editions.com/?p=22477 http://www.mypharma-editions.com/pharmaleads-annonce-lentree-en-phase-2-du-pl37-chef-de-file-dune-nouvelle-classe-danalgesiques/feed 0 http://www.mypharma-editions.com/cellectis-et-lefs-vont-inaugurer-leur-partenariat http://www.mypharma-editions.com/cellectis-et-lefs-vont-inaugurer-leur-partenariat#comments Fri, 25 Nov 2011 08:08:48 +0000 morgdave http://www.mypharma-editions.com/?p=22474 http://www.mypharma-editions.com/cellectis-et-lefs-vont-inaugurer-leur-partenariat/feed 0 http://www.mypharma-editions.com/nanobiotix-obtient-un-nouveau-financement-dun-million-deuros-doseo http://www.mypharma-editions.com/nanobiotix-obtient-un-nouveau-financement-dun-million-deuros-doseo#comments Wed, 23 Nov 2011 16:52:55 +0000 morgdave http://www.mypharma-editions.com/?p=22457 http://www.mypharma-editions.com/nanobiotix-obtient-un-nouveau-financement-dun-million-deuros-doseo/feed 0 http://www.mypharma-editions.com/pfizer-va-faire-lacquisition-dexcaliard http://www.mypharma-editions.com/pfizer-va-faire-lacquisition-dexcaliard#comments Tue, 22 Nov 2011 16:50:59 +0000 morgdave http://www.mypharma-editions.com/?p=22440 http://www.mypharma-editions.com/pfizer-va-faire-lacquisition-dexcaliard/feed 0 http://www.mypharma-editions.com/cerenis-le-dr-richard-pasternak-nomme-au-conseil-d%e2%80%99administration http://www.mypharma-editions.com/cerenis-le-dr-richard-pasternak-nomme-au-conseil-d%e2%80%99administration#comments Tue, 22 Nov 2011 13:53:45 +0000 morgdave http://www.mypharma-editions.com/?p=22431 http://www.mypharma-editions.com/cerenis-le-dr-richard-pasternak-nomme-au-conseil-d%e2%80%99administration/feed 0 http://www.mypharma-editions.com/cerenis-john-paolini-nomme-directeur-medical http://www.mypharma-editions.com/cerenis-john-paolini-nomme-directeur-medical#comments Tue, 22 Nov 2011 12:06:20 +0000 morgdave http://www.mypharma-editions.com/?p=22428 http://www.mypharma-editions.com/cerenis-john-paolini-nomme-directeur-medical/feed 0 http://www.mypharma-editions.com/pharnext-termine-le-recrutement-pour-son-essai-clinique-de-phase-ii-avec-son-1er-pleomedicament%e2%84%a2 http://www.mypharma-editions.com/pharnext-termine-le-recrutement-pour-son-essai-clinique-de-phase-ii-avec-son-1er-pleomedicament%e2%84%a2#comments Tue, 22 Nov 2011 08:59:50 +0000 morgdave http://www.mypharma-editions.com/?p=22418 http://www.mypharma-editions.com/pharnext-termine-le-recrutement-pour-son-essai-clinique-de-phase-ii-avec-son-1er-pleomedicament%e2%84%a2/feed 0 http://www.mypharma-editions.com/ucb-rachete-les-activites-pharmaceutiques-de-lectus-therapeutics http://www.mypharma-editions.com/ucb-rachete-les-activites-pharmaceutiques-de-lectus-therapeutics#comments Tue, 22 Nov 2011 08:40:42 +0000 morgdave http://www.mypharma-editions.com/?p=22413 http://www.mypharma-editions.com/ucb-rachete-les-activites-pharmaceutiques-de-lectus-therapeutics/feed 1 http://www.mypharma-editions.com/gilead-sciences-acquiert-pharmasset-pour-11-milliards-de-dollars http://www.mypharma-editions.com/gilead-sciences-acquiert-pharmasset-pour-11-milliards-de-dollars#comments Tue, 22 Nov 2011 08:34:26 +0000 morgdave http://www.mypharma-editions.com/?p=22410 http://www.mypharma-editions.com/gilead-sciences-acquiert-pharmasset-pour-11-milliards-de-dollars/feed 1 http://www.mypharma-editions.com/psoriasis-hybrigenics-lance-l%e2%80%99etude-clinique-de-phase-ii-de-l%e2%80%99inecalcitol http://www.mypharma-editions.com/psoriasis-hybrigenics-lance-l%e2%80%99etude-clinique-de-phase-ii-de-l%e2%80%99inecalcitol#comments Mon, 21 Nov 2011 09:31:21 +0000 morgdave http://www.mypharma-editions.com/?p=22398 http://www.mypharma-editions.com/psoriasis-hybrigenics-lance-l%e2%80%99etude-clinique-de-phase-ii-de-l%e2%80%99inecalcitol/feed 0 http://www.mypharma-editions.com/bioalliance-pharma-remporte-les-palmes-de-la-croissance-en-france-du-palmares-%c2%ab-deloitte-technology-fast-50-2011-%c2%bb http://www.mypharma-editions.com/bioalliance-pharma-remporte-les-palmes-de-la-croissance-en-france-du-palmares-%c2%ab-deloitte-technology-fast-50-2011-%c2%bb#comments Fri, 18 Nov 2011 10:18:41 +0000 morgdave http://www.mypharma-editions.com/?p=22352 http://www.mypharma-editions.com/bioalliance-pharma-remporte-les-palmes-de-la-croissance-en-france-du-palmares-%c2%ab-deloitte-technology-fast-50-2011-%c2%bb/feed 0 http://www.mypharma-editions.com/glaxosmithkline-gsk-lance-un-fonds-d%e2%80%99innovation-des-sciences-de-la-vie-de-36-millions-d%e2%80%99euros-au-canada http://www.mypharma-editions.com/glaxosmithkline-gsk-lance-un-fonds-d%e2%80%99innovation-des-sciences-de-la-vie-de-36-millions-d%e2%80%99euros-au-canada#comments Fri, 18 Nov 2011 07:50:11 +0000 morgdave http://www.mypharma-editions.com/?p=22347 http://www.mypharma-editions.com/glaxosmithkline-gsk-lance-un-fonds-d%e2%80%99innovation-des-sciences-de-la-vie-de-36-millions-d%e2%80%99euros-au-canada/feed 0 http://www.mypharma-editions.com/traitement-anti-vih-gilead-sciences-finalise-un-accord-avec-tibotec-pharmaceuticals http://www.mypharma-editions.com/traitement-anti-vih-gilead-sciences-finalise-un-accord-avec-tibotec-pharmaceuticals#comments Thu, 17 Nov 2011 08:39:05 +0000 morgdave http://www.mypharma-editions.com/?p=22333 http://www.mypharma-editions.com/traitement-anti-vih-gilead-sciences-finalise-un-accord-avec-tibotec-pharmaceuticals/feed 1 http://www.mypharma-editions.com/bioalliance-pharma-avancees-sur-la-commercialisation-de-loramyc%c2%ae http://www.mypharma-editions.com/bioalliance-pharma-avancees-sur-la-commercialisation-de-loramyc%c2%ae#comments Tue, 15 Nov 2011 09:44:50 +0000 morgdave http://www.mypharma-editions.com/?p=22281 http://www.mypharma-editions.com/bioalliance-pharma-avancees-sur-la-commercialisation-de-loramyc%c2%ae/feed 0 http://www.mypharma-editions.com/sclerose-en-plaques-genzyme-annonce-les-resultats-positifs-d%e2%80%99une-etude-de-phase-3-avec-alemtuzumab http://www.mypharma-editions.com/sclerose-en-plaques-genzyme-annonce-les-resultats-positifs-d%e2%80%99une-etude-de-phase-3-avec-alemtuzumab#comments Mon, 14 Nov 2011 08:13:29 +0000 morgdave http://www.mypharma-editions.com/?p=22249 http://www.mypharma-editions.com/sclerose-en-plaques-genzyme-annonce-les-resultats-positifs-d%e2%80%99une-etude-de-phase-3-avec-alemtuzumab/feed 0 http://www.mypharma-editions.com/herpes-resultats-encourageants-grace-aux-meganucleases-de-cellectis http://www.mypharma-editions.com/herpes-resultats-encourageants-grace-aux-meganucleases-de-cellectis#comments Mon, 14 Nov 2011 07:55:51 +0000 morgdave http://www.mypharma-editions.com/?p=22247 http://www.mypharma-editions.com/herpes-resultats-encourageants-grace-aux-meganucleases-de-cellectis/feed 0 http://www.mypharma-editions.com/le-portefeuille-de-genopole%c2%ae-suscite-l%e2%80%99interet-du-japonais-daiichi-sankyo http://www.mypharma-editions.com/le-portefeuille-de-genopole%c2%ae-suscite-l%e2%80%99interet-du-japonais-daiichi-sankyo#comments Sat, 12 Nov 2011 13:58:24 +0000 morgdave http://www.mypharma-editions.com/?p=22241 http://www.mypharma-editions.com/le-portefeuille-de-genopole%c2%ae-suscite-l%e2%80%99interet-du-japonais-daiichi-sankyo/feed 1 http://www.mypharma-editions.com/diabete-cellectis-prend-une-longueur-d%e2%80%99avance-dans-la-recherche-de-futurs-traitements http://www.mypharma-editions.com/diabete-cellectis-prend-une-longueur-d%e2%80%99avance-dans-la-recherche-de-futurs-traitements#comments Thu, 10 Nov 2011 15:05:07 +0000 morgdave http://www.mypharma-editions.com/?p=22208 http://www.mypharma-editions.com/diabete-cellectis-prend-une-longueur-d%e2%80%99avance-dans-la-recherche-de-futurs-traitements/feed 0 http://www.mypharma-editions.com/neovacs%c2%ae-succes-de-l%e2%80%99etude-de-phase-iii-sur-lifn%ce%b1-kinoide%c2%ae-dans-le-lupus http://www.mypharma-editions.com/neovacs%c2%ae-succes-de-l%e2%80%99etude-de-phase-iii-sur-lifn%ce%b1-kinoide%c2%ae-dans-le-lupus#comments Wed, 09 Nov 2011 09:19:48 +0000 morgdave http://www.mypharma-editions.com/?p=22176 http://www.mypharma-editions.com/neovacs%c2%ae-succes-de-l%e2%80%99etude-de-phase-iii-sur-lifn%ce%b1-kinoide%c2%ae-dans-le-lupus/feed 0 http://www.mypharma-editions.com/merck-serono-et-ablynx-etendent-leur-partenariat-dans-le-domaine-de-l%e2%80%99arthrose http://www.mypharma-editions.com/merck-serono-et-ablynx-etendent-leur-partenariat-dans-le-domaine-de-l%e2%80%99arthrose#comments Wed, 09 Nov 2011 08:09:16 +0000 morgdave http://www.mypharma-editions.com/?p=22166 http://www.mypharma-editions.com/merck-serono-et-ablynx-etendent-leur-partenariat-dans-le-domaine-de-l%e2%80%99arthrose/feed 0 http://www.mypharma-editions.com/cancer-du-foie-transgene-et-jennerex-annoncent-l%e2%80%99inclusion-du-premier-patient-dans-un-essai-clinique-de-phase-iib-sur-jx594tg6006 http://www.mypharma-editions.com/cancer-du-foie-transgene-et-jennerex-annoncent-l%e2%80%99inclusion-du-premier-patient-dans-un-essai-clinique-de-phase-iib-sur-jx594tg6006#comments Fri, 04 Nov 2011 12:06:45 +0000 morgdave http://www.mypharma-editions.com/?p=22086 http://www.mypharma-editions.com/cancer-du-foie-transgene-et-jennerex-annoncent-l%e2%80%99inclusion-du-premier-patient-dans-un-essai-clinique-de-phase-iib-sur-jx594tg6006/feed 0 http://www.mypharma-editions.com/bioalliance-pharma-clonidine-lauriad%e2%84%a2-obtient-le-statut-de-%c2%ab-medicament-orphelin-%c2%bb-en-europe http://www.mypharma-editions.com/bioalliance-pharma-clonidine-lauriad%e2%84%a2-obtient-le-statut-de-%c2%ab-medicament-orphelin-%c2%bb-en-europe#comments Wed, 02 Nov 2011 17:52:51 +0000 morgdave http://www.mypharma-editions.com/?p=22039 http://www.mypharma-editions.com/bioalliance-pharma-clonidine-lauriad%e2%84%a2-obtient-le-statut-de-%c2%ab-medicament-orphelin-%c2%bb-en-europe/feed 0 http://www.mypharma-editions.com/genfit-l%e2%80%99universite-de-lille-2-renforce-sa-participation-dans-le-capital http://www.mypharma-editions.com/genfit-l%e2%80%99universite-de-lille-2-renforce-sa-participation-dans-le-capital#comments Wed, 02 Nov 2011 14:41:45 +0000 morgdave http://www.mypharma-editions.com/?p=22033 http://www.mypharma-editions.com/genfit-l%e2%80%99universite-de-lille-2-renforce-sa-participation-dans-le-capital/feed 0 http://www.mypharma-editions.com/exonhit-et-allergan-renouvellent-leur-collaboration-strategique http://www.mypharma-editions.com/exonhit-et-allergan-renouvellent-leur-collaboration-strategique#comments Wed, 02 Nov 2011 07:47:46 +0000 morgdave http://www.mypharma-editions.com/?p=22009 http://www.mypharma-editions.com/exonhit-et-allergan-renouvellent-leur-collaboration-strategique/feed 0 http://www.mypharma-editions.com/maladies-auto-immunes-biogen-idec-et-portola-entament-une-collaboration-mondiale http://www.mypharma-editions.com/maladies-auto-immunes-biogen-idec-et-portola-entament-une-collaboration-mondiale#comments Thu, 27 Oct 2011 13:28:30 +0000 morgdave http://www.mypharma-editions.com/?p=21939 http://www.mypharma-editions.com/maladies-auto-immunes-biogen-idec-et-portola-entament-une-collaboration-mondiale/feed 0 http://www.mypharma-editions.com/genfit-met-en-place-des-groupes-d%e2%80%99experts-pour-les-developpements-cliniques-de-gft505 http://www.mypharma-editions.com/genfit-met-en-place-des-groupes-d%e2%80%99experts-pour-les-developpements-cliniques-de-gft505#comments Wed, 26 Oct 2011 08:18:13 +0000 morgdave http://www.mypharma-editions.com/?p=21913 http://www.mypharma-editions.com/genfit-met-en-place-des-groupes-d%e2%80%99experts-pour-les-developpements-cliniques-de-gft505/feed 0 http://www.mypharma-editions.com/txcell-resultats-positifs-pour-ovasave%c2%ae-dans-la-maladie-de-crohn http://www.mypharma-editions.com/txcell-resultats-positifs-pour-ovasave%c2%ae-dans-la-maladie-de-crohn#comments Wed, 26 Oct 2011 08:10:35 +0000 morgdave http://www.mypharma-editions.com/?p=21911 http://www.mypharma-editions.com/txcell-resultats-positifs-pour-ovasave%c2%ae-dans-la-maladie-de-crohn/feed 0 http://www.mypharma-editions.com/epilepsie-ucb-soutient-l%e2%80%99ouverture-d%e2%80%99un-centre-pour-patients-en-chine http://www.mypharma-editions.com/epilepsie-ucb-soutient-l%e2%80%99ouverture-d%e2%80%99un-centre-pour-patients-en-chine#comments Tue, 25 Oct 2011 12:40:27 +0000 morgdave http://www.mypharma-editions.com/?p=21902 http://www.mypharma-editions.com/epilepsie-ucb-soutient-l%e2%80%99ouverture-d%e2%80%99un-centre-pour-patients-en-chine/feed 0 http://www.mypharma-editions.com/hepatite-b-gilead-et-globeimmune-collaborent-au-developpement-de-vaccins-therapeutiques http://www.mypharma-editions.com/hepatite-b-gilead-et-globeimmune-collaborent-au-developpement-de-vaccins-therapeutiques#comments Tue, 25 Oct 2011 12:31:13 +0000 morgdave http://www.mypharma-editions.com/?p=21900 http://www.mypharma-editions.com/hepatite-b-gilead-et-globeimmune-collaborent-au-developpement-de-vaccins-therapeutiques/feed 0 http://www.mypharma-editions.com/taconic-et-oncodesign-vont-developper-des-outils-de-recherche-en-oncologie http://www.mypharma-editions.com/taconic-et-oncodesign-vont-developper-des-outils-de-recherche-en-oncologie#comments Tue, 25 Oct 2011 09:38:42 +0000 morgdave http://www.mypharma-editions.com/?p=21893 http://www.mypharma-editions.com/taconic-et-oncodesign-vont-developper-des-outils-de-recherche-en-oncologie/feed 0 http://www.mypharma-editions.com/cellectis-nomination-de-philippe-valachs-au-poste-de-secretaire-general http://www.mypharma-editions.com/cellectis-nomination-de-philippe-valachs-au-poste-de-secretaire-general#comments Tue, 25 Oct 2011 09:14:31 +0000 morgdave http://www.mypharma-editions.com/?p=21886 http://www.mypharma-editions.com/cellectis-nomination-de-philippe-valachs-au-poste-de-secretaire-general/feed 0 http://www.mypharma-editions.com/david-meeker-nomme-directeur-general-de-genzyme http://www.mypharma-editions.com/david-meeker-nomme-directeur-general-de-genzyme#comments Mon, 24 Oct 2011 15:28:34 +0000 morgdave http://www.mypharma-editions.com/?p=21870 http://www.mypharma-editions.com/david-meeker-nomme-directeur-general-de-genzyme/feed 1 http://www.mypharma-editions.com/genfit-une-etude-en-milieu-hospitalier-demontre-laction-de-gft505-sur-le-foie http://www.mypharma-editions.com/genfit-une-etude-en-milieu-hospitalier-demontre-laction-de-gft505-sur-le-foie#comments Thu, 20 Oct 2011 17:03:06 +0000 morgdave http://www.mypharma-editions.com/?p=21821 http://www.mypharma-editions.com/genfit-une-etude-en-milieu-hospitalier-demontre-laction-de-gft505-sur-le-foie/feed 0 http://www.mypharma-editions.com/hpv-fin-du-recrutement-des-patients-dans-l%e2%80%99essai-de-phase-i-de-procervix-le-vaccin-therapeutique-de-genticel http://www.mypharma-editions.com/hpv-fin-du-recrutement-des-patients-dans-l%e2%80%99essai-de-phase-i-de-procervix-le-vaccin-therapeutique-de-genticel#comments Thu, 20 Oct 2011 12:57:28 +0000 morgdave http://www.mypharma-editions.com/?p=21815 http://www.mypharma-editions.com/hpv-fin-du-recrutement-des-patients-dans-l%e2%80%99essai-de-phase-i-de-procervix-le-vaccin-therapeutique-de-genticel/feed 0 http://www.mypharma-editions.com/vivalis-et-geovax-signent-un-accord-de-bioproduction-de-vaccins-mva-contre-le-vih http://www.mypharma-editions.com/vivalis-et-geovax-signent-un-accord-de-bioproduction-de-vaccins-mva-contre-le-vih#comments Thu, 20 Oct 2011 08:08:50 +0000 morgdave http://www.mypharma-editions.com/?p=21809 http://www.mypharma-editions.com/vivalis-et-geovax-signent-un-accord-de-bioproduction-de-vaccins-mva-contre-le-vih/feed 0 http://www.mypharma-editions.com/ipsen-et-syntaxin-vont-developper-des-therapies-innovantes-a-partir-de-la-toxine-botulique http://www.mypharma-editions.com/ipsen-et-syntaxin-vont-developper-des-therapies-innovantes-a-partir-de-la-toxine-botulique#comments Thu, 20 Oct 2011 06:38:19 +0000 morgdave http://www.mypharma-editions.com/?p=21803 http://www.mypharma-editions.com/ipsen-et-syntaxin-vont-developper-des-therapies-innovantes-a-partir-de-la-toxine-botulique/feed 0 http://www.mypharma-editions.com/genfit-le-dr-catherine-larue-nommee-vice-presidente-executive-biomarqueurs http://www.mypharma-editions.com/genfit-le-dr-catherine-larue-nommee-vice-presidente-executive-biomarqueurs#comments Tue, 18 Oct 2011 12:31:36 +0000 morgdave http://www.mypharma-editions.com/?p=21775 http://www.mypharma-editions.com/genfit-le-dr-catherine-larue-nommee-vice-presidente-executive-biomarqueurs/feed 0 http://www.mypharma-editions.com/david-sourdive-prend-la-presidence-du-pole-de-competitivite-medicen http://www.mypharma-editions.com/david-sourdive-prend-la-presidence-du-pole-de-competitivite-medicen#comments Sat, 15 Oct 2011 08:51:36 +0000 morgdave http://www.mypharma-editions.com/?p=21719 http://www.mypharma-editions.com/david-sourdive-prend-la-presidence-du-pole-de-competitivite-medicen/feed 0 http://www.mypharma-editions.com/alzheimer-accord-de-recherche-entre-exonhit-et-pfizer-pour-l%e2%80%99identification-de-biomarqueurs http://www.mypharma-editions.com/alzheimer-accord-de-recherche-entre-exonhit-et-pfizer-pour-l%e2%80%99identification-de-biomarqueurs#comments Tue, 11 Oct 2011 06:41:35 +0000 morgdave http://www.mypharma-editions.com/?p=21584 http://www.mypharma-editions.com/alzheimer-accord-de-recherche-entre-exonhit-et-pfizer-pour-l%e2%80%99identification-de-biomarqueurs/feed 0 http://www.mypharma-editions.com/hybrigenics-et-servier-signent-un-accord-de-licence-et-de-recherche http://www.mypharma-editions.com/hybrigenics-et-servier-signent-un-accord-de-licence-et-de-recherche#comments Mon, 10 Oct 2011 08:44:29 +0000 morgdave http://www.mypharma-editions.com/?p=21576 http://www.mypharma-editions.com/hybrigenics-et-servier-signent-un-accord-de-licence-et-de-recherche/feed 0 http://www.mypharma-editions.com/vih-gilead-et-boehringer-ingelheim-signent-un-accord-de-licence http://www.mypharma-editions.com/vih-gilead-et-boehringer-ingelheim-signent-un-accord-de-licence#comments Thu, 06 Oct 2011 19:15:04 +0000 morgdave http://www.mypharma-editions.com/?p=21515 http://www.mypharma-editions.com/vih-gilead-et-boehringer-ingelheim-signent-un-accord-de-licence/feed 0 http://www.mypharma-editions.com/sanofi-resultats-positifs-pour-son-medicament-experimental-oral-teriflunomide-dans-la-sep http://www.mypharma-editions.com/sanofi-resultats-positifs-pour-son-medicament-experimental-oral-teriflunomide-dans-la-sep#comments Thu, 06 Oct 2011 06:29:49 +0000 morgdave http://www.mypharma-editions.com/?p=21496 http://www.mypharma-editions.com/sanofi-resultats-positifs-pour-son-medicament-experimental-oral-teriflunomide-dans-la-sep/feed 1 http://www.mypharma-editions.com/hybrigenics-alain-munoz-nomme-administrateur-independant http://www.mypharma-editions.com/hybrigenics-alain-munoz-nomme-administrateur-independant#comments Wed, 05 Oct 2011 12:19:09 +0000 morgdave http://www.mypharma-editions.com/?p=21487 http://www.mypharma-editions.com/hybrigenics-alain-munoz-nomme-administrateur-independant/feed 0 http://www.mypharma-editions.com/nouvelle-gouvernance-pour-stallergenes http://www.mypharma-editions.com/nouvelle-gouvernance-pour-stallergenes#comments Mon, 03 Oct 2011 17:12:14 +0000 morgdave http://www.mypharma-editions.com/?p=21433 http://www.mypharma-editions.com/nouvelle-gouvernance-pour-stallergenes/feed 0 http://www.mypharma-editions.com/hybrigenics-realise-une-levee-de-fonds-de-300-000-euros http://www.mypharma-editions.com/hybrigenics-realise-une-levee-de-fonds-de-300-000-euros#comments Mon, 03 Oct 2011 14:13:40 +0000 morgdave http://www.mypharma-editions.com/?p=21430 http://www.mypharma-editions.com/hybrigenics-realise-une-levee-de-fonds-de-300-000-euros/feed 0